BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its wholly-owned European subsidiary, Sucampo Pharma Europe Ltd., received notice that all of the Marketing Authorization Applications (MAA) for lubiprostone, 24 mcg, (AMITIZA®) for the indication of Chronic Idiopathic Constipation in adults have been received and validated by the individual regulatory agencies in Belgium, Denmark, France, Germany, Ireland, the Netherlands, Spain, Sweden and the United Kingdom. The applications were submitted using the decentralized process with the United Kingdom serving as the reference member state. With the validation, the agencies will begin their formal review of the applications.
